

James Chih-Hsin Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5070242/publications.pdf>

Version: 2024-02-01

256
papers

27,499
citations

15466

65
h-index

5965

160
g-index

257
all docs

257
docs citations

257
times ranked

18358
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	0.8	2,854
2	AZD9291 in <i>EGFR</i> Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699.	13.9	1,802
3	Afatinib versus cisplatin-based chemotherapy for <i>EGFR</i> mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
4	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). <i>Journal of Clinical Oncology</i> , 2011, 29, 2866-2874.	0.8	1,368
5	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , The, 2016, 17, 1497-1508.	5.1	1,279
6	Afatinib versus gefitinib as first-line treatment of patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	5.1	950
7	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 528-538.	5.1	904
8	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3375-3382.	0.8	741
9	Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	13.9	691
10	Checkpoint Inhibitors in Metastatic <i>EGFR</i> -Mutated Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 403-407.	0.5	653
11	Preclinical Comparison of Osimertinib with Other <i>EGFR</i> -TKIs in <i>EGFR</i> -Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016, 22, 5130-5140.	3.2	554
12	Alectinib in Crizotinib-Refractory <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	0.8	548
13	Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter <i>EGFR</i> Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 433-440.	0.8	471
14	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	0.8	470
15	Impact of <i>EGFR</i> Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 595-605.	3.0	469
16	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
17	Lung cancers with acquired resistance to <i>EGFR</i> inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33.	3.3	410
18	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2369-2379.	0.8	410

#	ARTICLE	IF	CITATIONS
19	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 539-548.	5.1	390
20	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	5.1	353
21	Amivantamab in EGFR Exon 20 Insertion-“Mutated Non-“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
22	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 373-386.	5.1	300
23	Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3342-3350.	0.8	285
24	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965.	0.8	280
25	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-“Dysregulated Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3101-3109.	0.8	252
26	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	0.8	230
27	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016, 7, 12404-12413.	0.8	209
28	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 793-799.	0.5	199
29	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	196
30	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 567-572.	0.5	188
31	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 124-129.	0.5	187
32	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	0.5	186
33	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9503-9503.	0.8	179
34	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020, 15, 803-815.	0.5	178
35	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4079-4085.	0.8	171
36	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5,2 169 8, 1132-1143.		

#	ARTICLE	IF	CITATIONS
37	ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3926-3934.	0.8	158
38	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3258-3266.	0.8	153
39	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790Mâ€“Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 933-939.	0.5	152
40	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Nonâ€“Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1754-1761.	0.5	145
41	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4034.	0.8	141
42	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Letters</i> , 2013, 328, 144-151.	3.2	135
43	Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1872-1880.	0.5	132
44	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 94-101.	1.1	126
45	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 553-559.	0.5	123
46	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Nonâ€“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 633-643.	0.5	122
47	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 107-116.	5.2	121
48	Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136.	5.0	101
49	Monotherapy Administration of Sorafenib in Patients With Nonâ€“Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753.	0.5	100
50	Diarrhea associated with afatinib: an oral ErbB family blocker. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 729-736.	1.1	98
51	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ð²-blockers. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	96
52	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 891-902.	5.2	92
53	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 162-168.	0.5	90
54	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	0.5	85

#	ARTICLE	IF	CITATIONS
55	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8009-8009.	0.8	81
56	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Science Translational Medicine, 2016, 8, 368ra172.	5.8	78
57	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer, 2017, 116, 175-185.	2.9	76
58	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
59	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2011, 11, 430.	1.1	74
60	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	0.8	74
61	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Molecular Oncology, 2013, 7, 112-120.	2.1	70
62	Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2014, 9, 1171-1179.	0.5	70
63	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. Journal of Thoracic Oncology, 2022, 17, 411-422.	0.5	70
64	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer, 2018, 125, 273-281.	0.9	69
65	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of Thoracic Oncology, 2018, 13, 1897-1905.	0.5	68
66	Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC. Clinical Cancer Research, 2011, 17, 6459-6466.	3.2	66
67	Symptom and Quality of Life Benefit of Afatinib in Advanced Non-Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1). Journal of Thoracic Oncology, 2013, 8, 229-237.	0.5	66
68	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2016, 11, 1140-1152.	0.5	64
69	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020.	0.8	63
70	Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clinical Cancer Research, 2012, 18, 3470-3477.	3.2	62
71	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget, 2015, 6, 10415-10431.	0.8	62
72	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2016, 94, 46-53.	0.9	60

#	ARTICLE	IF	CITATIONS
73	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. Journal of Clinical Oncology, 2012, 30, LBA7500-LBA7500.	0.8	60
74	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1418-1425.	0.5	59
75	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology, 2016, 34, 9002-9002.	0.8	59
76	Treatment of Advanced Non-“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2014, 15, 173-181.	1.1	56
77	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 2018, 19, e465-e479.	1.1	56
78	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer, 2019, 144, 2887-2896.	2.3	56
79	Exon 16-“Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-“Positive Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 50-61.	0.5	56
80	Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1720-1725.	0.5	54
81	Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non-“Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum. Journal of Thoracic Oncology, 2012, 7, 973-981.	0.5	52
82	Tepotinib Efficacy and Safety in Patients with <i>MET</i> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126.	3.2	52
83	Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. Journal of Magnetic Resonance Imaging, 2012, 36, 387-396.	1.9	51
84	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Journal of Thoracic Oncology, 2017, 12, 1247-1256.	0.5	48
85	Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. Lung Cancer, 2014, 85, 230-238.	0.9	47
86	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British Journal of Clinical Pharmacology, 2018, 84, 1156-1169.	1.1	47
87	Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.. Journal of Clinical Oncology, 2016, 34, 9016-9016.	0.8	47
88	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer, 2015, 88, 208-214.	0.9	46
89	Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1385-1392.	0.5	45
90	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. European Journal of Cancer, 2014, 50, 2219-2230.	1.3	44

#	ARTICLE	IF	CITATIONS
91	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , 2014, 83, 174-181.	0.9	43
92	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018, 78, 3350-3362.	0.4	42
93	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , 2016, 23, 86.	2.6	41
94	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	1.2	41
95	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 99-110.	1.2	41
96	Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2017, 110, 7-13.	0.9	40
97	Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. <i>Journal of Nanobiotechnology</i> , 2019, 17, 89.	4.2	40
98	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK $\text{â€}rearranged lung cancer. EMBO Molecular Medicine, 2019, 11, e10581.$	3.3	40
99	Benefits and limitations of real-world evidence: lessons from <i>EGFR</i> mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 965-977.	1.1	40
100	Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0119135.	1.1	38
101	Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis. <i>Journal of Geriatric Oncology</i> , 2015, 6, 38-45.	0.5	38
102	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1663-1669.	0.5	37
103	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i> -mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 992-1002.	3.2	36
104	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 324-343.	0.5	34
105	Lung Cancer in Republic of China. <i>Journal of Thoracic Oncology</i> , 2021, 16, 519-527.	0.5	34
106	Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8004-8004.	0.8	34
107	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013, 82, 420-425.	0.9	33
108	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 324-332.e1.	1.1	33

#	ARTICLE	IF	CITATIONS
109	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017, 22, 1075-1083.	1.9	31
110	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-EGFR-mutated small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 117, 107-115.	1.3	31
111	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	1.2	31
112	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 91-100.	0.5	31
113	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study. <i>Journal of Clinical Oncology</i> , 2014, 32, 8017-8017.	0.8	31
114	Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One Helical Cell-Penetrating Peptide or Glutathione and Tween 80. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1998.	1.8	30
115	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 9008-9008.	0.8	30
116	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
117	Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3662-3670.	0.8	29
118	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018, 126, 368-374.	0.3	29
119	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019, 133, 103-109.	0.9	29
120	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). <i>Journal of Clinical Oncology</i> , 2021, 39, 9077-9077.	0.8	29
121	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989028.	1.4	28
122	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. <i>Journal of Clinical Oncology</i> , 2016, 34, 9044-9044.	0.8	28
123	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016, 17, e77-e94.	1.1	27
124	The Role of Interleukin 1 β in the Pathogenesis of Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100001.	0.6	27
125	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	0.9	26
126	Survival of Patients with Small Cell Lung Carcinoma in Taiwan. <i>Oncology</i> , 2012, 82, 19-24.	0.9	25

#	ARTICLE	IF	CITATIONS
127	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637.	1.4	25
128	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19.	0.9	25
129	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 663-673.	2.5	24
130	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 346-352.	0.9	23
131	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 445-451.	1.2	23
132	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 38-42.	2.9	23
133	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1324-1332.	2.9	23
134	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. <i>PLoS ONE</i> , 2013, 8, e80276.	1.1	23
135	Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 418-424.	1.1	22
136	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 22-27.	0.9	22
137	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2016, 11, 370-379.	0.5	21
138	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1588-1594.	0.5	21
139	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 27-34.	1.1	21
140	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 106-114.	1.3	20
141	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 274-290.	1.4	20
142	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018, 11, 131-141.	1.1	20
143	Phase I Study of the Focal Adhesion Kinase Inhibitor BI-853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. <i>Targeted Oncology</i> , 2019, 14, 57-65.	1.7	20
144	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. <i>Oncologist</i> , 2019, 24, e1417-e1425.	1.9	19

#	ARTICLE	IF	CITATIONS
145	Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. <i>Journal of Thoracic Oncology</i> , 2015, 10, e95-e96.	0.5	18
146	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8013-8013.	0.8	18
147	AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8016-8016.	0.8	18
148	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9517-9517.	0.8	18
149	Profile of the <i>therascreen</i> ® <i>EGFR</i> RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1251-1257.	1.5	17
150	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018, 19, e361-e372.	1.1	17
151	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800.	0.5	17
152	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
153	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2006-2006.	0.8	17
154	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9001-9001.	0.8	17
155	Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9007-9007.	0.8	17
156	First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 150-160.	1.1	16
157	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 51-55.	1.0	16
158	Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 31-41.	3.4	16
159	CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 1231-1242.	0.5	16
160	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017, 19, 4.	1.8	15
161	Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862.	1.7	15
162	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	15

#	ARTICLE	IF	CITATIONS
163	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS ONE, 2015, 10, e0145936.	1.1	15
164	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. Frontiers in Oncology, 2022, 12, 834704.	1.3	15
165	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer, 2015, 16, 137-143.	1.1	14
166	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	1.0	14
167	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.	1.1	14
168	Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/ gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy.. Journal of Clinical Oncology, 2012, 30, 7557-7557.	0.8	14
169	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9022-9022.	0.8	14
170	First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.. Journal of Clinical Oncology, 2017, 35, 9094-9094.	0.8	14
171	Survival Following Surgery with or without Adjuvant Chemotherapy for Stage IIIA Non-Small Cell Lung Cancer: An East Asian Population-Based Study. Oncologist, 2012, 17, 1294-1302.	1.9	13
172	Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy. Clinical Cancer Research, 2013, 19, 5292-5299.	3.2	13
173	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer, 2014, 22, 1189-1197.	1.0	13
174	Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS). Journal of Thoracic Oncology, 2014, 9, 1411-1417.	0.5	13
175	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist, 2015, 20, 1051-1057.	1.9	13
176	The impact of smoking on the effectiveness of immune checkpoint inhibitors – a systematic review and meta-analysis. Acta Oncologica, 2020, 59, 96-100.	0.8	13
177	AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.. Journal of Clinical Oncology, 2015, 33, 8000-8000.	0.8	13
178	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget, 2017, 8, 41474-41486.	0.8	13
179	First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs, 2013, 73, 357-369.	4.9	12
180	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes and Cancer, 2018, 57, 513-521.	1.5	12

#	ARTICLE	IF	CITATIONS
181	Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 11506-11506.	0.8	12
182	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069.	0.8	12
183	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, e103-e112.	1.1	11
184	Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clinical Lung Cancer, 2019, 20, e609-e618.	1.1	11
185	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	0.6	11
186	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. JTO Clinical and Research Reports, 2021, 2, 100140.	0.6	11
187	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncology, 2021, 17, 4237-4247.	1.1	11
188	Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer, 2021, 159, 96-106.	0.9	11
189	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046.	0.8	11
190	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association, 2018, 117, 326-331.	0.8	10
191	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9094-9094.	0.8	10
192	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 76-82.	0.9	10
193	Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. Journal of Neuro-Oncology, 2013, 115, 61-70.	1.4	9
194	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. Journal of Cancer, 2016, 7, 1515-1523.	1.2	9
195	Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9061-9061.	0.8	9
196	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 991-1003.	1.1	8
197	Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients – A Taiwanese study. Journal of the Formosan Medical Association, 2019, 118, 230-236.	0.8	8
198	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1817-1826.	0.8	8

#	ARTICLE	IF	CITATIONS
199	24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. Journal of Clinical Oncology, 2018, 36, 9026-9026.	0.8	8
200	The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 837.	1.7	7
201	Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. Drugs, 2011, 71, 79-88.	4.9	6
202	A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncology, The, 2013, 14, 564-565.	5.1	6
203	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. Expert Opinion on Pharmacotherapy, 2018, 19, 851-864.	0.9	6
204	Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. Journal of the Formosan Medical Association, 2019, 118, 995-1004.	0.8	6
205	<p>Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 125-130.	1.3	6
206	Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 272.	1.7	6
207	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. Journal of Clinical Oncology, 2012, 30, 7558-7558.	0.8	6
208	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	0.8	6
209	Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. Journal of Clinical Oncology, 2016, 34, e20501-e20501.	0.8	6
210	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9075-TPS9075.	0.8	6
211	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 2022, 18, 1793-1799.	1.1	6
212	Osimertinib plus Selumetinib in <i>EGFR</i>-Mutated Nonâ€“Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical Cancer Research, 2022, 28, 4222-4231.	3.2	6
213	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 2022, 40, 9015-9015.	0.8	6
214	Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer, 2020, 148, 177-178.	0.9	5
215	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer, 2021, 154, 113-117.	0.9	5
216	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9072-9072.	0.8	5

#	ARTICLE	IF	CITATIONS
217	457â€¦KEYNOTE-495/KeylPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for nonâ€“small cell lung cancer (NSCLC). , 2021, 9, A485-A485.		5
218	Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?. <i>Lancet Oncology</i> , The, 2019, 20, 602-603.	5.1	4
219	The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8072-8072.	0.8	4
220	Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive <i>EGFR</i>-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9053-9053.	0.8	4
221	Nazartinib (EGF816) in patients with treatment-naïve <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9574-9574.	0.8	4
222	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020, 52, 284-291.	1.3	4
223	Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) nonâ€“small cell lung cancer (NSCLC) with PD-L1 â‰¥ 50% and without actionable genomic alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3162-TPS3162.	0.8	4
224	Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitorâ€”the End or Beginning?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 305-307.	0.5	3
225	HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9139-TPS9139.	0.8	3
226	Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).. <i>Journal of Clinical Oncology</i> , 2016, 34, e14100-e14100.	0.8	3
227	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9071-9071.	0.8	3
228	Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2016, 9, 474-480.	0.3	2
229	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysisâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 1138.	3.4	2
230	A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19013-e19013.	0.8	2
231	Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3588-3588.	0.8	2
232	A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9631-TPS9631.	0.8	2
233	Reply to E.R. Haspinger et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 863-864.	0.8	1
234	Reply to F. de Marinis et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 865-865.	0.8	1

#	ARTICLE	IF	CITATIONS
235	Interview: Changing advanced lung cancer into chronic disease. Lung Cancer Management, 2014, 3, 23-28.	1.5	1
236	Real-World or Controlled Clinical Trial Data in Real-World Practice. Journal of Thoracic Oncology, 2018, 13, 470-472.	0.5	1
237	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. JTO Clinical and Research Reports, 2021, 2, 100142.	0.6	1
238	Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. Journal of Clinical Oncology, 2017, 35, 8547-8547.	0.8	1
239	TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. Journal of Clinical Oncology, 2015, 33, TPS8109-TPS8109.	0.8	1
240	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. Journal of Clinical Oncology, 2016, 34, e20507-e20507.	0.8	1
241	Tepotinib in Asian patients with advanced NSCLC with <i>MET</i> exon 14 (<i>MET</i> ex14) skipping.. Journal of Clinical Oncology, 2022, 40, 9120-9120.	0.8	1
242	Small-Cell Lung Cancer Treatment: Where is the Target?. Journal of Thoracic Oncology, 2012, 7, 1327-1328.	0.5	0
243	Angiokinase inhibitors in non-small-cell lung cancer. Clinical Investigation, 2015, 5, 47-59.	0.0	0
244	Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. Journal of Clinical Oncology, 2017, 35, 694-695.	0.8	0
245	Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: a database of 693 cases. Video Journal of Biomedicine, 0, .	0.0	0
246	Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1426-1428.	0.5	0
247	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC. JTO Clinical and Research Reports, 2021, 2, 100099.	0.6	0
248	Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm+) and progression on gefitinib.. Journal of Clinical Oncology, 2014, 32, TPS8121-TPS8121.	0.8	0
249	Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS2631-TPS2631.	0.8	0
250	The impact of diabetes mellitus on early cervical cancer in ſsia: A population-based cohort study.. Journal of Clinical Oncology, 2014, 32, e16501-e16501.	0.8	0
251	Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. Journal of Clinical Oncology, 2015, 33, e19061-e19061.	0.8	0
252	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. Journal of Clinical Oncology, 2015, 33, 8043-8043.	0.8	0

#	ARTICLE	IF	CITATIONS
253	TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9106-TPS9106.	0.8	0
254	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. <i>Translational Lung Cancer Research</i> , 2012, 1, 227-9.	1.3	0
255	Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive <i>ALK+</i> NSCLC in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9072-9072.	0.8	0
256	Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. <i>Cancer Research</i> , 2022, 82, CT561-CT561.	0.4	0